fda tirzepatide decision Grants a New Indication for Obesity Management GLP-1 Drugs: FDA “Re-Confirms” Decision

Clinical trials show blood pressure reductions averaging 2-6 mmHg systolic in many patients, though weight loss itself contributes to this effect

Tirzepatides pathway signaling

Mullins CA, Gannaban RB, Khan MS, Shah H, Siddik MAB, Hegde VK, Reddy PH, Shin AC (2020) Neural underpinnings of obesity: the role of oxidative stress and inflammation in the brain

These measurements, combined with genetic insights, may support more targeted treatment conversations rather than assuming all eligible patients will respond identically

Contact your healthcare provider if dizziness is severe, persistent, or associated with fainting